Device Trial Radar · NCT07317102
Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
Mar 16, 2026
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Insulet CorporationPublic (PODD)
- Sponsor type
- Industry
- First posted
- Jan 5, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the Omnipod 5 Automated Insulin Delivery System (referred to as the Omnipod 5 System) in a real-world setting.
Conditions
- Diabetes
- Type 1 Diabetes
- Diabetes Mellitus
Interventions
Omnipod 5Device
The Omnipod 5 Automated Insulin Delivery System (Omnipod 5 System) is a tubeless insulin pump with a mono-hormonal insulin delivery system designed to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in people aged 2 years and older who require insulin. The Omnipod 5 System is intended to function as an automated insulin delivery system when used with compatible Continuous Glucose Monitoring (CGM) systems.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the percentage of time in the 70 - 180 mg/dL rangeTime frame: Change in percentage of time in specified range between Baseline and 12-months following first initiation of automated mode
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
CHU Angers
Angers, France · Recruiting
CHU Besançon - Hôpital de Jean Minjoz
Besançon, France · Recruiting
APHP Hopital Avicenne
Bobigny, France · Recruiting
21 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.